Waters Corporation $WAT Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its holdings in Waters Corporation (NYSE:WAT) by 58.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,618 shares of the medical instruments supplier’s stock after purchasing an additional 1,707 shares during the quarter. GAMMA Investing LLC’s holdings in Waters were worth $1,732,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Janus Henderson Group PLC grew its position in Waters by 27.0% in the 1st quarter. Janus Henderson Group PLC now owns 1,638,772 shares of the medical instruments supplier’s stock valued at $488,028,000 after buying an additional 348,379 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Waters by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock worth $602,921,000 after buying an additional 8,590 shares in the last quarter. Invesco Ltd. raised its position in shares of Waters by 32.3% during the 3rd quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier’s stock worth $441,446,000 after buying an additional 359,596 shares in the last quarter. Veritas Asset Management LLP boosted its holdings in shares of Waters by 112.3% in the fourth quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier’s stock valued at $471,447,000 after acquiring an additional 656,436 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Waters by 17.0% during the first quarter. Principal Financial Group Inc. now owns 1,019,289 shares of the medical instruments supplier’s stock valued at $303,556,000 after acquiring an additional 148,320 shares during the period. 94.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. UBS Group upped their target price on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Wall Street Zen cut Waters from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. The Goldman Sachs Group boosted their price objective on Waters from $380.00 to $425.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Evercore restated an “outperform” rating and issued a $420.00 price objective on shares of Waters in a report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Waters presently has an average rating of “Moderate Buy” and a consensus price target of $418.10.

Waters Stock Performance

WAT opened at $399.62 on Friday. The firm has a market cap of $39.24 billion, a PE ratio of 99.66, a P/E/G ratio of 2.41 and a beta of 1.19. The company has a quick ratio of 1.13, a current ratio of 0.77 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $372.78 and a 200-day simple moving average of $345.13. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15.

Waters (NYSE:WAT) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same period in the previous year, the firm earned $2.95 earnings per share. Waters’s revenue for the quarter was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. As a group, equities analysts predict that Waters Corporation will post 14.56 EPS for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.